Contact Center Industry News

TMCNet:  Batu Biologics Recruits Renowned Cancer Immunologist to Scientific Advisory Board

[June 30, 2014]

Batu Biologics Recruits Renowned Cancer Immunologist to Scientific Advisory Board

SAN DIEGO --(Business Wire)--

Batu Biologics Inc, an immunotherapy company developing ValloVaxTM, the first anti-angiogenic cancer vaccine, announced today the appointment of Boris Minev, M.D. to the company's Scientific Advisory Board (SAB). Dr. Minev is an internationally renowned key opinion leader in tumor immunology, currently serving as Principal Investigator, Director, Laboratory of Tumor Immunology and Immunotherapy at Moores UCSD Cancer Center, as well as Director of Immunotherapy and Translational Oncology at Genelux Corporation. Dr. Minev will assist Batu Biologics in advancing ValloVaxTM through FDA clinical trials, which are anticipated to begin in early 2015.

"Having worked in the field of tumor immunology and on the development of the first tumor vaccine to be approved by a regulatory body (Melacine), I am fascinated by novel approaches to cancer immunotherapy," Dr. Minev said. "The approach being developed by Batu Biologics is completely unique in that this is the first time the blood vessels that feed the tumor are being used as a target of immunotherapy. This provides a completely different approach to cancer therapy since: a) blood vessels do not mutate like tumors mutate, thus reducing chances of the cells becoming resistant to therapy; b) for every single blood vessel cell that is killed, approximately 200-300 tumor cells die, thus higher potential for efficacy exists; and c) tumor blood vessels are in direct contact with the immune system via the blood. In contrast, tumr cells are very difficult to completely eradicate due to areas inside the tumor that lack sufficient circulation and are impenetrable by immune system cells."

The ValloVaxTM product is based on blood vessel cells generated in the laboratory in a manner which makes them resemble tumor blood vessels. The immune response against the "artificial tumor blood vessels" is believed to result in the selective killing of tumor blood vessels.

"Leveraging the translational oncology experience of Dr. Minev, especially his work in the area of peptide vaccines and nanotechnology, will not only accelerate the FDA process for our cancer vaccine, but will also provide synergies in the area of new product pipeline development," said Samuel Wagner, President and CEO of Batu Biologics. "Being in the middle of a crowd funding campaign, we anticipate the recruitment of a major scientist like Dr. Minev to attract significant attention to our efforts."

Earlier this month, Batu Biologics announced efforts to raise $100,000 through donation-based crowd funding to support completion of the company's preclinical research. Link to the campaign:

About Batu Biologics

Founded in 2013, Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. The company's products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax.

With the recent successes of immunotherapy in a variety of tumors, Batu Biologics believes there is an increasing unmet need for non-toxic immune modulators that can augment efficacy of existing therapeutics. Our team is motivated to bring novel therapeutics to the forefront of medical research that use the power of the body's own immune system to extend life expectancy. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014.

Corporate Address:
9255 Towne Centre Drive
Suite 450
San Diego, CA (News - Alert) 92121

Laboratory Address:
Janssen Research and Development
3210 Merryfield Row
San Diego, CA 92121

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...